Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)

Post - Marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients

This study aims to establish the safety, tolerability, and efficacy of Vytorin (R) (Ezetimibe + Simvastatin) (SCH 465981) on a select population of Filipinos with hypercholesterolemia.

Inclusion Criteria:

• Outpatient men or women, age 18 years and above
• Patients with primary (heterozygous familial and non-familial) hypercholesterolemia

Exclusion Criteria:

• Known hypersensitivity to Ezetimibe and Simvastatin
• Moderate to severe hepatic insufficiency
• Persistent elevation of serum transaminase levels of more than 1.5 times the upper limit of normal
• Pregnancy or lactation
• Concomitant intake of bile acid sequestrants (resins), nicotinic acid (niacin), fibric acid (fibrates), or cyclosporine